Protara Therapeutics Inc

This non-binding management proposal asks stockholders to approve, on an advisory basis, the compensation paid to the Company’s named executive officers as disclosed in the proxy statement. Management frames the vote as a check on overall compensation philosophy and implementation — emphasizing pay-for-performance alignment, use of equity incentives, and retention and recruitment needs in the life sciences sector. The advisory nature means the board is not legally obligated to follow the result, but states it will take the voting outcome into account when setting future pay. The Company highlights that compensation is overseen by the independent compensation committee, informed by an independent compensation consultant (Aon in 2025), and that the structure includes base salary, performance-based annual bonuses tied to corporate and individual objectives, and equity awards with typical multi-year vesting. Prior engagement and voting history are relevant: the company notes strong prior support (approximately 90% approval in 2025), signaling current investor alignment but also creating expectations for continued responsiveness. Key governance context includes the Company’s clawback policy and limits on director/executive compensation practices; the compensation committee assesses risks associated with compensation. A ‘FOR’ recommendation reflects management’s view that current programs incentivize desired outcomes and are competitively necessary. An informed analyst should weigh the advisory vote result, compensation quantum and realized pay (Pay Versus Performance disclosures) against clinical and operational milestones to judge whether pay drives long-term shareholder value.

This non-binding management proposal asks stockholders to indicate their preferred frequency (one, two or three years) for future advisory say-on-pay votes. Management and the board recommend an annual vote (one year), citing prior stockholder preference expressed in 2020 and a governance stance favoring frequent engagement and responsiveness to investor views. The vote is procedural but signals stockholder appetite for oversight frequency: annual votes allow shareholders to register opinions more frequently on compensation policies and outcomes, while multi-year votes reduce administrative burden and may be preferred where compensation programs are stable. The Company notes SEC requirements permit up to a three-year interval; it chooses annual given its history and stockholder feedback. For sophisticated analysis, consider the company’s stage (clinical-stage biotech with active development milestones) — where annual investor feedback may be particularly valuable as programs advance and pay outcomes hinge on trial progress. The board’s recommendation is driven by a desire to retain alignment and investor confidence; however, investors preferring longer intervals might argue for reduced noise and administrative costs. Because the result is advisory and determined by plurality, the practical consequence is reputational and may influence future compensation committee behavior rather than directly altering governance rules.

Management seeks shareholder approval to enlarge the equity reserve under the 2024 Equity Incentive Plan by 5,000,000 shares, effectively more than doubling the plan’s available shares to 9,300,000. The board frames this as necessary to preserve the Company’s ability to attract, retain and motivate employees, executives and non-employee directors — a common and material need in competitive life sciences labor markets. The filing documents that, as of April 15, 2026, only 287,441 shares remained available across equity plans (285,541 under the 2024 Plan), with 8.7 million shares subject to outstanding awards, supporting management’s argument that available capacity is constrained. Importantly, the plan includes shareholder-protective features: no automatic evergreen, explicit minimum vesting provisions with limited exceptions, prohibition on repricing without stockholder approval, double-trigger change-in-control protections, limits on director annual compensation, and clawback policy coverage — all of which management highlights to mitigate dilution and governance concerns. The board recommends approval as it believes failure to increase the reserve would impair competitive compensation practices and could harm the Company’s human capital and program execution. Analysts should weigh the dilutive impact of the increase (the amendment would represent about 9% of outstanding shares as of the record date) against the operational need to continue making equity grants tied to value-creating milestones. The vote is a standard equity plan amendment requiring majority approval of votes cast; if approved, detailed amendment text is included as Appendix A.

Management proposes a charter amendment to increase authorized common shares from 100 million to 200 million (with total authorized shares set at 210 million including preferred). The board presents this as a prudential measure to ensure sufficient authorized but unissued shares are available for future financing, equity incentive grants, conversions, or strategic transactions without the delay and expense of seeking further shareholder approval. The filing details the existing commitments as of April 15, 2026: 55.06 million shares outstanding, nearly 10.0 million reserved for option/award exercises, and up to 18.76 million reserved for preferred conversion and warrant exercises, leaving only ~16.18 million unreserved — a limited headroom. The proposed increase would greatly expand the company’s flexibility to issue shares when needed for capital raising, business development, or employee compensation. Management notes the amendment is not intended as an anti-takeover device, but acknowledges additional shares could be used in defensive contexts; analysts should therefore consider potential governance implications and the dilutive impact if, when and how the new shares are issued. The required vote is a simple majority of votes cast; if approved the amendment becomes effective upon filing with the Delaware Secretary of State. The board recommends FOR to avoid constraints on strategic and financing options.

The board requests authorization to add an officer exculpation provision to the charter consistent with the Delaware General Corporation Law, extending to officers similar monetary liability protections that directors commonly have — but only to the fullest extent permitted by law. Management argues this limited exculpation shields officers from monetary damages for breaches of the duty of care while preserving accountability for breaches of duty of loyalty, bad faith, intentional misconduct, knowing legal violations, improper personal benefits, and derivative claims — i.e., the principal statutory exceptions. The board’s rationale centers on recruiting and retaining qualified executive talent and reducing the chilling effect of prospective litigation and defense costs on timely business decision-making. From a governance perspective, proponents contend the measure brings the company in line with common practice among Delaware issuers and peers in the industry. Critics may argue it further insulates executives from accountability and could reduce deterrence against negligent behavior; however, the retained exceptions and indemnification and D&O insurance mitigate those concerns. The amendment becomes effective on filing and requires a majority of outstanding shares; the board recommends approval as a measured alignment with current Delaware law that balances operational needs and fiduciary protections.